127 related articles for article (PubMed ID: 21781668)
1. Studies on the differential sensitivity between diabetic and non-diabetic human erythrocytes to monoacetyl dapsone hydroxylamine-mediated methaemoglobin formation in vitro.
Coleman MD; Ogg MS; Holmes JL; Gardiner JM; Jacobus DP
Environ Toxicol Pharmacol; 1996 Apr; 1(2):97-102. PubMed ID: 21781668
[TBL] [Abstract][Full Text] [Related]
2. Methaemoglobin formation due to nitrite, disulfiram, 4-aminophenol and monoacetyldapsone hydroxylamine in diabetic and non-diabetic human erythrocytes in vitro.
Coleman MD; Hayes PJ; Jacobus DP
Environ Toxicol Pharmacol; 1998 Jan; 5(1):61-7. PubMed ID: 21781851
[TBL] [Abstract][Full Text] [Related]
3. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. III: Effect of diabetes.
Coleman MD; Simpson J; Jacobus DP
Biochem Pharmacol; 1994 Oct; 48(7):1341-7. PubMed ID: 7945431
[TBL] [Abstract][Full Text] [Related]
4. The methaemoglobin forming and GSH depleting effects of dapsone and monoacetyl dapsone hydroxylamines in human diabetic and non-diabetic erythrocytes in vitro.
Coleman MD; Holden LJ
Environ Toxicol Pharmacol; 2004 May; 17(1):55-9. PubMed ID: 21782713
[TBL] [Abstract][Full Text] [Related]
5. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro.
Coleman MD; Jacobus DP
Biochem Pharmacol; 1993 Mar; 45(5):1027-33. PubMed ID: 8461032
[TBL] [Abstract][Full Text] [Related]
6. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro.
Coleman MD; Pahal KK; Gardiner JM
J Pharm Pharmacol; 1996 Apr; 48(4):401-6. PubMed ID: 8794991
[TBL] [Abstract][Full Text] [Related]
7. Effects of oxidised alpha-lipoic acid and alpha-tocopherol on xenobiotic-mediated methaemoglobin formation in diabetic and non-diabetic human erythrocytes in-vitro.
Coleman MD; Walker CL
Environ Toxicol Pharmacol; 2000 Jan; 8(2):127-132. PubMed ID: 10867372
[TBL] [Abstract][Full Text] [Related]
8. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. IV: Implications for the development of agranulocytosis.
Coleman MD; Simpson J; Jacobus DP
Biochem Pharmacol; 1994 Oct; 48(7):1349-54. PubMed ID: 7945432
[TBL] [Abstract][Full Text] [Related]
9. The use of xenobiotic-mediated methaemoglobin formation to assess the effects of thyroid hormones on diabetic and non-diabetic human erythrocytic oxidant defence mechanisms in vitro.
Coleman MD; Gaskin CA; Fernandes S; Khanderia L
Environ Toxicol Pharmacol; 2003 Jan; 13(1):15-9. PubMed ID: 21782644
[TBL] [Abstract][Full Text] [Related]
10. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro--II. Movement of dapsone across a semipermeable membrane into erythrocytes and plasma.
Coleman MD; Jacobus DP
Biochem Pharmacol; 1993 Oct; 46(8):1363-8. PubMed ID: 8240384
[TBL] [Abstract][Full Text] [Related]
11. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system.
Tingle MD; Coleman MD; Park BK
Br J Clin Pharmacol; 1990 Dec; 30(6):829-38. PubMed ID: 2288829
[TBL] [Abstract][Full Text] [Related]
12. Effects of dihydrolipoic acid (DHLA), α-lipoic acid. N-acetyl cysteine and ascorbate on xenobiotic-mediated methaemoglobin formation in human erythrocytes in vitro.
Coleman MD; Taylor CT
Environ Toxicol Pharmacol; 2003 Sep; 14(3):121-7. PubMed ID: 21782671
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antioxidants dihydrolipoic acid (DHLA) and probucol on xenobiotic-mediated methaemoglobin formation in diabetic and non-diabetic human erythrocytes in vitro(1).
Coleman MD; Baker CD
Environ Toxicol Pharmacol; 2001 Mar; 9(4):161-167. PubMed ID: 11292579
[TBL] [Abstract][Full Text] [Related]
14. Use of in vitro methaemoglobin generation to study antioxidant status in the diabetic erythrocyte.
Coleman MD
Biochem Pharmacol; 2000 Nov; 60(10):1409-16. PubMed ID: 11020442
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced methaemoglobinaemia. Treatment issues.
Coleman MD; Coleman NA
Drug Saf; 1996 Jun; 14(6):394-405. PubMed ID: 8828017
[TBL] [Abstract][Full Text] [Related]
16. A preliminary evaluation of a novel method to monitor a triple antioxidant combination (vitamins E, C and α-lipoic acid) in diabetic volunteers using in vitro methaemoglobin formation.
Coleman MD; Fernandes S; Khanderia L
Environ Toxicol Pharmacol; 2003 Jun; 14(1-2):69-75. PubMed ID: 21782664
[TBL] [Abstract][Full Text] [Related]
17. Bioactivation of benzocaine to a methaemoglobin-forming metabolite by rat and human microsomes in vitro.
Coleman MD; Taylor CH
Environ Toxicol Pharmacol; 1997 Feb; 3(1):47-52. PubMed ID: 21781757
[TBL] [Abstract][Full Text] [Related]
18. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency.
Pirmohamed M; Williams D; Tingle MD; Barry M; Khoo SH; O'Mahony C; Wilkins EG; Breckenridge AM; Park BK
AIDS; 1996 May; 10(5):501-7. PubMed ID: 8724041
[TBL] [Abstract][Full Text] [Related]
19. Dapsone toxicity: some current perspectives.
Coleman MD
Gen Pharmacol; 1995 Nov; 26(7):1461-7. PubMed ID: 8690232
[TBL] [Abstract][Full Text] [Related]
20. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions.
Reilly TP; Woster PM; Svensson CK
J Pharmacol Exp Ther; 1999 Mar; 288(3):951-9. PubMed ID: 10027831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
